Jazz Pharma reaffirms FY2022 revenue guidance at J.P. Morgan conference

Jazz Pharmaceuticals plc

Company expects to meet previously announced total, neuroscience and oncology revenue guidance for FY2022.
Presentation includes corporate overview and financial update; no change to existing guidance ranges.
No specific revenue or earnings figures disclosed in the filing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Jazz Pharmaceuticals plc updated its year ended December 31, 2022 guidance (reaffirmed).

Period: year ended December 31, 2022
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

the Company’s expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance ranges for the year ended December 31, 2022.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001193125-23-004151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.